$50m-plus deal gives Daiichi Sankyo option to Amplimmune's T-cell inhibitor
This article was originally published in Scrip
Daiichi Sankyo is aiming to strengthen its pipeline for autoimmune disorders through an option deal with the private US firm Amplimmune for a novel but still preclinical stage immunomodulating molecule, AMP-110.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.